Jaguar Health, Inc. (JAGX)

NASDAQ: JAGX · IEX Real-Time Price · USD
0.282
-0.017 (-5.53%)
Aug 16, 2022 11:42 AM EDT - Market open
-5.53%
Market Cap 21.96M
Revenue (ttm) 5.72M
Net Income (ttm) -58.57M
Shares Out 77.87M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,005,259
Open 0.293
Previous Close 0.299
Day's Range 0.270 - 0.295
52-Week Range 0.246 - 3.750
Beta 1.67
Analysts Buy
Price Target 11.09 (+3,832.6%)
Earnings Date Aug 15, 2022

About JAGX

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug in... [Read more...]

Industry Pharmaceuticals
Founded 2013
CEO Lisa Conte
Employees 52
Stock Exchange NASDAQ
Ticker Symbol JAGX
Full Company Profile

Financial Performance

In 2021, Jaguar Health's revenue was $4.34 million, a decrease of -53.81% compared to the previous year's $9.39 million. Losses were -$52.60 million, 55.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for JAGX stock is "Buy." The 12-month stock price forecast is 11.09, which is an increase of 3,832.62% from the latest price.

Price Target
$11.09
(3,832.62% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gallup Survey Estimates Nearly 30 Million U.S. Dog Owners Have Experienced Canine Cancer, with Many Saying it Negativ...

The emotional toll canine cancer takes on dog owners demonstrates the need for the Canine Cancer Care Index. Only 18% of dog owners who have been through such an ordeal gave a perfect score to their ove...

Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemothera...

New patent bolsters intellectual property protection for the company's core target indication for crofelemer Crofelemer is the subject of the company's OnTarget study, an ongoing pivotal Phase 3 clinica...

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / August 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective August 5, 2022, the Company granted 12,500 restricted stoc...

Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Form...

Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee SAN FRANCISCO, CA / ACCESSWIRE / July 5, 2022 / Jaguar Health, ...

Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Cana...

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months Service agreement of up to $5.0 million payable in unregistered Jaguar stock to SynWorld to supp...

Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at...

SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress, ...

Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as P...

Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval fro...

Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cance...

Diarrhea is also a prevalent side effect in dogs undergoing cancer treatment; managing diarrhea can be important to maintain successful cancer treatment in both humans and dogs SAN FRANCISCO, CA / ACCES...

Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders

All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Annual Meet...

Jaguar Health to Participate in BIO International Convention (BIO 2022)

Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea (CTD) and inflammatory bowel disease (IBD)...

Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental H...

Drug Discovery Collaboration Will Leverage the Botanical Drug Development Expertise of Both Companies SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Healt...

Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicine...

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory ...

Jaguar Health Announces Presentation of an Investigator-initiated Evaluation of Crofelemer for a Severe Congenital Di...

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory ...

Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index

"Canine Cancer: Take C.H.A.R.G.E." (Canine Health And ReGistry Exchange) Based on Nationwide Gallup Poll of Pet Owners and Initial Assessment of More Than 35,000 Canine Medical Records Initial Data from...

Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!

Click here to RSVP for this in-person, outdoor event Human and doggy swag will be available*, and the event will feature presentations by well-known veterinary cancer specialists, including Dr. Sue Canc...

TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health

SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd. ("TAG") issued an analyst report today on the company.

Jaguar Health Announces Launch of Mytesi Telehealth Program

This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically App...

Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials

Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021 Core initiatives: On...

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 6, 2022, the Company granted 50,000 restricted stock unit...

UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 F...

Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Healt...

Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corpo...

Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Healt...

Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to...

Canalevia® Would Be the First and Only Treatment for EID in Dogs To Receive Any Type of Approval From FDA SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jagu...

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug fo...

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jag...

Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022

SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital Mark...

Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Awa...